Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study for the Safety, Efficacy, Pharmacokinetic and Pharmacodynamics Evaluation of Amcenestrant (SAR439859), Administered Orally as Monotherapy, Then in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor-positive Advanced Breast Cancer

NCT03284957 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT03284957
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03284957 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study for the Safety, Efficacy, Pharmacokinetic and Pharmacodynamics Evaluation of Amcenestrant (SAR439859), Administered Orally as Monotherapy, Then in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor-positive Advanced Breast Cancer
Lead sponsor
Sanofi
Phase
Phase 1/2
Overall status
Terminated
Start date
September 20, 2017
Completion date
November 8, 2024
Enrollment
136 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer